Savara Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SVRA Nasdaq 2836 www.savarapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Savara Inc.

Savara Announces New Employment Inducement Grant - Jul 18th, 2025 2:05 pm
3 Promising Penny Stocks With Market Caps At Least $300M - Jul 1st, 2025 6:05 am
Savara Independent Director Acquires 177% More Stock - Jun 25th, 2025 4:39 am
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) - May 27th, 2025 6:05 am
Biogen strikes RNAi deal with City; Aurion withdraws IPO - May 27th, 2025 5:53 am
Savara Announces Participation in Jefferies Global Healthcare Conference - May 22nd, 2025 7:05 am
Savara Inc. (SVRA): Analysts See 212% Upside Potential - May 21st, 2025 9:16 am
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 - May 18th, 2025 12:30 pm
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update - May 13th, 2025 2:05 pm
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference - May 12th, 2025 2:05 pm
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference - May 1st, 2025 2:05 pm
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - Apr 7th, 2025 2:05 pm
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Mar 27th, 2025 5:05 am
Savara Gets Up to $200 Million Loan From Hercules Capital - Mar 26th, 2025 3:22 pm
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Mar 26th, 2025 2:45 pm
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Mar 26th, 2025 2:05 pm
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 - Mar 17th, 2025 6:05 am
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Mar 6th, 2025 6:05 am
Savara Announces Participation in the Leerink Global Healthcare Conference - Mar 3rd, 2025 2:15 pm
Positive Signs As Multiple Insiders Buy Savara Stock - Feb 8th, 2025 5:57 am